{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T07:16:42Z","timestamp":1788419802781,"version":"build-2803163510"},"reference-count":28,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T00:00:00Z","timestamp":1788393600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Refractory ocular myasthenia gravis (OMG) remains a significant therapeutic challenge with limited evidence-based biologic therapies. This study aimed to evaluate the effectiveness and safety of telitacicept, a recombinant B-lymphocyte stimulator receptor-antibody fusion protein, in refractory OMG.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      This retrospective, single-center observational study assessed clinical outcomes, immunological biomarkers, and safety following add-on telitacicept therapy in refractory OMG. Disease severity was evaluated using the Myasthenia Gravis Activities of Daily Living (MG-ADL), Quantitative Myasthenia Gravis (QMG), and Myasthenia Gravis Impairment Index (MGII) scales. Serum immunoglobulins, complement components, and CD19\n                      <jats:sup>+<\/jats:sup>\n                      B-cell counts were measured, and adverse events were systematically recorded.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Twelve patients with refractory OMG were included. Median baseline MG-ADL, QMG, and MGII scores were 5.5 (interquartile range [IQR] 5.0\u20136.0), 7.0 (IQR 5.3\u20138.0), and 16.0 (IQR 12.0\u201318.0), respectively. Statistically significant improvement was observed as early as week 1 (all\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0&amp;lt;\u00a00.05). By week 12, MG-ADL scores decreased by a median of 3.0 (95% CI: 2.0\u20134.0;\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0&amp;lt;\u00a00.001, r = 0.89), with consistent improvements in QMG and MGII scores (all\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0&amp;lt;\u00a00.01, all r &amp;gt; 0.85). Minimal symptom expression (MSE) was achieved in 7 of 12 patients (58.3%) within the 12-week period. The median daily prednisone dose was reduced from 15.0 mg (IQR 10.0\u201322.5) to 9.0 mg (IQR 5.0\u201313.8) by week 12 (median decrease: 7.5 mg, 95% CI: 2.5\u201313.5;\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0=\u00a00.031, r = 0.79), with 1 patient discontinuing corticosteroids by week 8. Telitacicept treatment was associated with reductions in serum IgG, IgA, and IgM levels, alongside increased levels of complement components. No serious adverse events, infections, or treatment discontinuations occurred.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Telitacicept was associated with rapid, sustained clinical improvement and a favorable safety profile in refractory OMG, which supports its potential role as an add-on therapeutic option.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1797461","type":"journal-article","created":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T06:44:37Z","timestamp":1788417877000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Effectiveness and safety of telitacicept in refractory ocular myasthenia gravis: a retrospective, real-world study"],"prefix":"10.3389","volume":"17","author":[{"given":"Chao","family":"Sun","sequence":"first","affiliation":[{"name":"Department of Neurology, Tangdu Hospital, The Fourth Military Medical University","place":["Xi\u2019an, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danni","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Neurology, Tangdu Hospital, The Fourth Military Medical University","place":["Xi\u2019an, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yonglan","family":"Tang","sequence":"additional","affiliation":[{"name":"Department of Neurology, Tangdu Hospital, The Fourth Military Medical University","place":["Xi\u2019an, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Biying","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Neurology, Tangdu Hospital, The Fourth Military Medical University","place":["Xi\u2019an, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rongjing","family":"Guo","sequence":"additional","affiliation":[{"name":"Department of Neurology, Tangdu Hospital, The Fourth Military Medical University","place":["Xi\u2019an, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Gao","sequence":"additional","affiliation":[{"name":"Department of Neurology, Tangdu Hospital, The Fourth Military Medical University","place":["Xi\u2019an, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangqi","family":"Cao","sequence":"additional","affiliation":[{"name":"Department of Neurology, Tangdu Hospital, The Fourth Military Medical University","place":["Xi\u2019an, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sijia","family":"Hao","sequence":"additional","affiliation":[{"name":"Department of Neurology, Tangdu Hospital, The Fourth Military Medical University","place":["Xi\u2019an, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingqing","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Neurology, Tangdu Hospital, The Fourth Military Medical University","place":["Xi\u2019an, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Neurology, Tangdu Hospital, The Fourth Military Medical University","place":["Xi\u2019an, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Chang","sequence":"additional","affiliation":[{"name":"Department of Neurology, Tangdu Hospital, The Fourth Military Medical University","place":["Xi\u2019an, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,3]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1001\/jama.2023.16872","article-title":"What is myasthenia gravis","volume":"331","author":"Marcus","year":"2024","journal-title":"JAMA"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.medcli.2023.04.006","article-title":"Myasthenia gravis. Update on diagnosis and therapy","volume":"161","author":"Garcia Estevez","year":"2023","journal-title":"Med Clin (Barc)"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1007\/s13311-021-01129-z","article-title":"Thymectomy and risk of generalization in patients with ocular myasthenia gravis: A multicenter retrospective cohort study","volume":"18","author":"Li","year":"2021","journal-title":"Neurotherapeutics"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1080\/08164622.2022.2029683","article-title":"Ocular myasthenia gravis: a review and practical guide for clinicians","volume":"105","author":"Shuey","year":"2022","journal-title":"Clin Exp Optom"},{"key":"B5","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1097\/wco.0000000000000775","article-title":"Ocular myasthenia gravis: updates on an elusive target","volume":"33","author":"Melson","year":"2020","journal-title":"Curr Opin Neurol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.pediatrneurol.2024.01.014","article-title":"Pediatric ocular myasthenia gravis: Single-center experience","volume":"153","author":"Kessi","year":"2024","journal-title":"Pediatr Neurol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/s40120-021-00292-x","article-title":"Risk factors for generalization in patients with ocular myasthenia gravis: A multicenter retrospective cohort study","volume":"11","author":"Guo","year":"2022","journal-title":"Neurol Ther"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1111\/ene.15292","article-title":"Association of immunosuppression treatment with generalization among patients with ocular myasthenia gravis: a propensity score analysis","volume":"29","author":"Ruan","year":"2022","journal-title":"Eur J Neurol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1177\/17562864231163819","article-title":"Immunotherapy for ocular myasthenia gravis: an observational study in Japan","volume":"16","author":"Narita","year":"2023","journal-title":"Ther Adv Neurol Disord"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-024-02101-9","article-title":"Efgartigimod: a review in generalised myasthenia gravis","volume":"84","author":"Blair","year":"2024","journal-title":"Drugs"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-018-0875-9","article-title":"Eculizumab: a review in generalized myasthenia gravis","volume":"78","author":"Dhillon","year":"2018","journal-title":"Drugs"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1002\/mus.25973","article-title":"B cells in the pathophysiology of myasthenia gravis","volume":"57","author":"Yi","year":"2018","journal-title":"Muscle Nerve"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-immunol-083122-044829","article-title":"B cell-directed therapy in autoimmunity","volume":"42","author":"Abeles","year":"2024","journal-title":"Annu Rev Immunol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1111\/ene.14391","article-title":"Efficacy and safety of rituximab in myasthenia gravis: a French multicentre real-life study","volume":"27","author":"Dos Santos","year":"2020","journal-title":"Eur J Neurol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/s1474-4422(23)00375-7","article-title":"Anti-CD19 CAR T cells for refractory myasthenia gravis","volume":"22","author":"Haghikia","year":"2023","journal-title":"Lancet Neurol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-021-01591-1","article-title":"Telitacicept: first approval","volume":"81","author":"Dhillon","year":"2021","journal-title":"Drugs"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1111\/ene.16322","article-title":"A multicenter, randomized, open-label, phase 2 clinical study of telitacicept in adult patients with generalized myasthenia gravis","volume":"31","author":"Yin","year":"2024","journal-title":"Eur J Neurol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1002\/brb3.71157","article-title":"Add-on telitacicept significantly improves outcome of patients with refractory ocular myasthenia gravis a real-world case series","volume":"16","author":"Lin","year":"2026","journal-title":"Brain Behav"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1212\/nxi.0000000000200436","article-title":"AChR autoantibody pathogenic properties are heterogeneously distributed and undergo temporal changes among patients with myasthenia gravis","volume":"12","author":"Khani-Habibabadi","year":"2025","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2505984122","article-title":"Therapeutic IgG- and IgM-specific proteases disarm the acetylcholine receptor autoantibodies that drive myasthenia gravis pathology","volume":"122","author":"Bayer","year":"2025","journal-title":"Proc Natl Acad Sci USA"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2024-334404","article-title":"C5 complement inhibition versus FcRn modulation in generalised myasthenia gravis","volume":"96","author":"Huntemann","year":"2025","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000001169","article-title":"Heterogeneity of acetylcholine receptor autoantibody-mediated complement activity in patients with myasthenia gravis","volume":"9","author":"Obaid","year":"2022","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1056\/nejm198209233071301","article-title":"Functional activities of autoantibodies to acetylcholine receptors and the clinical severity of myasthenia gravis","volume":"307","author":"Drachman","year":"1982","journal-title":"N Engl J Med"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-022-11048-4","article-title":"Individualized regimen of low-dose rituximab monotherapy for new-onset AChR-positive generalized myasthenia gravis","volume":"269","author":"Du","year":"2022","journal-title":"J Neurol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1212\/nxi.0000000000000831","article-title":"High kappa free light chain is a potential biomarker for double seronegative and ocular myasthenia gravis","volume":"7","author":"Wilf-Yarkoni","year":"2020","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2414719","article-title":"A phase 3 trial of telitacicept for systemic lupus erythematosus","volume":"393","author":"van Vollenhoven","year":"2025","journal-title":"N Engl J Med"},{"key":"B27","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1093\/rheumatology\/kead265","article-title":"Efficacy and safety of telitacicept in primary Sjogren's syndrome: a randomized, double-blind, placebo-controlled, phase 2 trial","volume":"63","author":"Xu","year":"2024","journal-title":"Rheumatol (Oxford)"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2023-224854","article-title":"Telitacicept in patients with active systemic lupus erythematosus: results of a phase 2b, randomised, double-blind, placebo-controlled trial","volume":"83","author":"Wu","year":"2024","journal-title":"Ann Rheum Dis"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1797461\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T06:44:39Z","timestamp":1788417879000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1797461\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,3]]},"references-count":28,"alternative-id":["10.3389\/fimmu.2026.1797461"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1797461","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,3]]},"article-number":"1797461"}}